Clara Foods mengembangkan pepsin bebas hewan pertama di dunia

Clara Foods telah menciptakan pepsin bebas hewan pertama di dunia untuk penggunaan komersial, menargetkan keberlanjutan dan kekhawatiran etis dalam produksi enzim. Produk ini mempertahankan kinerja fungsional dan cocok untuk aplikasi makanan dan farmasi, termasuk kebutuhan vegan, halal, dan kosher. Inovasi ini menyoroti pergeseran menuju metode produksi alternatif di pasar pepsin.

Clara Foods mengumumkan terobosan dalam teknologi enzim dengan pengembangan pepsin bebas hewan pertama di dunia yang tersedia untuk penggunaan komersial. Pepsin ini, enzim proteolitik esensial untuk pemecahan protein, mengatasi tantangan utama dalam keberlanjutan dan pengadaan etis sambil mempertahankan kinerja fungsional enzim tersebut.  nnProduk baru ini dirancang untuk aplikasi di sektor makanan dan farmasi. Produk tersebut memenuhi persyaratan standar vegan, halal, dan kosher, sehingga memperluas aksesibilitasnya di berbagai pasar. Menurut laporan industri, kemajuan ini mengurangi ketergantungan pada enzim turunan hewan tradisional, yang berpotensi mengubah dinamika pasar.  nnPengembangan ini terjadi di tengah permintaan yang meningkat untuk pepsin dalam solusi kesehatan pencernaan, farmasi, dan pengolahan makanan. Pasar pepsin global diproyeksikan berkembang dengan tingkat pertumbuhan tahunan majemuk 10% dari 2026 hingga 2034, didorong oleh kesadaran kesehatan dan inovasi dalam bioteknologi. Inovasi Clara Foods selaras dengan tren menuju pepsin sumber mikroba dan alternatif, serta varian dengan aktivitas tinggi.  nnKemajuan seperti ini mendukung pergeseran industri yang lebih luas, termasuk bioteknologi dan produk berskala fermentasi. Inovasi tersebut merespons preferensi konsumen terhadap bahan alami dan berkelanjutan, terutama di wilayah seperti Amerika Utara dan Asia Pasifik, di mana pasar mengalami pertumbuhan kuat. Meskipun biaya bahan baku dan persaingan dari protease lain menjadi tantangan, opsi bebas hewan ini membuka peluang baru bagi produsen.  nnEvolusi pasar pepsin menggarisbawahi peran produksi etis dan efisien dalam memenuhi permintaan global hingga 2034.

Artikel Terkait

Scientists in a lab celebrating conditional approval of iPS cell products for treating Parkinson's and heart disease.
Gambar dihasilkan oleh AI

Health ministry panel conditionally approves iPS cell products

Dilaporkan oleh AI Gambar dihasilkan oleh AI

A health ministry expert panel has conditionally approved two regenerative medicine products derived from induced pluripotent stem (iPS) cells for treating Parkinson's disease and severe heart disease. This marks a potential world first in commercializing Nobel Prize-winning stem cell technology. The approval, based on small-scale clinical trials confirming safety and presumed efficacy, requires post-market verification within seven years.

Functionality, convenience and value remain core drivers of innovation in the global food and beverage market, according to Innova’s Top Ten Trends of 2026. Affordability concerns are influencing retailers' strategies, while trends like plant-based proteins and occasion-based products gain prominence. Brands are also targeting senior health needs amid an ageing population.

Dilaporkan oleh AI

Researchers at Flinders University have developed a thin, flexible film using milk protein, starch, and nanoclay that fully breaks down in soil within 13 weeks. The material aims to serve as an eco-friendly alternative to single-use plastics for food packaging. The study, published in Polymers, highlights its potential to reduce plastic pollution.

Following an expert panel's recommendation last month, Japan's Health, Labor and Welfare Ministry on March 6 conditionally approved two iPS cell-derived regenerative medicines—the world's first commercialized such treatments—for severe heart failure and Parkinson's disease. The products carry conditions and time limits, with pricing and insurance coverage decisions next; sales could begin as early as summer 2026.

Dilaporkan oleh AI Fakta terverifikasi

Researchers in Brazil report that prolonged use of the proton pump inhibitor (PPI) omeprazole altered iron and calcium measures in adult rats and shifted how several minerals were distributed across organs—changes they say are consistent with higher risks of anemia and possible bone health harms. The authors and Brazil’s health regulator stress that PPIs remain effective for acid-related disorders, but warn against extended, unsupervised use.

Researchers at Adelaide University report that salcaprozate sodium (SNAC)—an absorption enhancer used in oral semaglutide tablets—was associated with changes in gut bacteria and inflammation markers in an animal study conducted over 21 days. The authors said the findings do not demonstrate harm in humans but argue that longer-term research is needed as oral options for obesity treatment expand.

Dilaporkan oleh AI

Lactoprot Deutschland, a specialist in milk and whey products, plans to expand its site in Leezen. Due to growth, the facility in Lübeck is reaching its limits. Part of the production is to be relocated to Leezen.

 

 

 

Situs web ini menggunakan cookie

Kami menggunakan cookie untuk analisis guna meningkatkan situs kami. Baca kebijakan privasi kami untuk informasi lebih lanjut.
Tolak